Advanced Search


Study ID Status Title Patient Level Data
204654 Recruiting Protocol to Characterize Severe Asthma Patient Experience of Treatment Benefit with an anti-IL5 with Clinical Trial Exit Interviews
204661 Completed PGx7612: Pharmacogenetic investigation of the association of the ADRB2 rare variant, Thr164Ile with severe asthma exacerbation
204663 Completed An exploratory study to assess the effect of topical application of Iodex® balm on local surface temperature using infra red thermal imaging technique
204664 Completed Meta-Analysis in sponsored studies MEA112997, MEA115588, and MEA115575 and a proof of concept investigator sponsored study CRT110184 of Mepolizumab in Severe Asthma
204673 Withdrawn A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 Plus Trametinib in Subjects with Small Cell Lung Cancer and Ras-Mutated Solid Tumors
204674 Recruiting An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of RELVAR administered in Korean subjects in usual practice.
204675 Recruiting Evaluating the effectiveness of the revised alli® pack information in helping pharmacy staff within the EU supply alli® appropriately.
204676 Completed A Study to Evaluate the Effects of Protein Supplementation in Attenuating the Decline in Performance Following Strenuous Concurrent Exercise
204678 Completed A single centre, open-label, parallel-group, single oral dose study to evaluate the pharmacokinetics, safety and tolerability of Pyrimethamine in healthy Japanese and Caucasian male subjects
204682 Terminated An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects with Type 2 Diabetes Mellitus
204685 Completed A 2-part randomized, double-blind (sponsor-unblinded), placebo-controlled, ascending dose and parallel group study of TLR4 agonist (GSK1795091) administered to healthy subjects
204686 Recruiting A Phase I, Open-Label Study of GSK1795091 Administered in Combination with Immunotherapies in Participants with Advanced Solid Tumors
204687 Recruiting Assessment of safety of GlaxoSmithKline (GSK) Vaccines’ quadrivalent seasonal influenza vaccine, Fluarix Tetra when administered according to the approved Prescribing Information in Korea.
204691 Recruiting A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
204697 Recruiting A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC)
204699 Completed A randomized double-blind (sponsor unblind) placebo controlled study in healthy subjects to evaluate: safety, tolerability, pharmacokinetics, and pharmacodynamics of the repeat doses of GSK2881078, the Selective Androgen Receptor Modulator with an open label dosing arm to evaluate the effect of CYP3A4 inhibition on pharmacokinetics of GSK2881078
204710 Recruiting A Multinational, Single Arm, Observational Study to Evaluate the Real-world Effectiveness and Pattern of Use of Mepolizumab in Patients with Severe Eosinophilic Asthma (204710: the REALITI-A study)
204715 Recruiting A study of single doses to evaluate the safety, tolerability, pharmacokinetics and target engagement of nebulised GSK3008348 in idiopathic pulmonary fibrosis patients, using positron emission tomography (PET) imaging
204716 Completed A 24-week, Phase III, open-label, non-comparative, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese hemodialysis subjects with anemia associated with chronic kidney disease who are not taking erythropoiesis stimulating agents
204725 Completed An Open Label, Randomized, Single Dose, Crossover study to determine the Pharmacokinetics of Three Tablet Formulations of GSK2798745 in Healthy Subjects
204729 Completed A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending Dose Escalating, 4 Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of Single Doses of GSK3179106, a REarranged during Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers
204731 Recruiting An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of TRIUMEQ administered in Korean subjects for treatment of HIV-1 infection in real life practice
204736 Completed Sun Protection Factor Determination (In vivo determination of the sun protection factor ISO 24444) (61-SPF-iM)
204738 Completed The effects of 2 consecutive days of multiple highintensity exercise bouts on cognitive function, mood and fatigue state in well-trained intermittent sports players.
204739 Completed Study to investigate the initial stages of enamel erosion in vivo



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.